Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Net Income (2016 - 2025)

Lineage Cell Therapeutics' Net Income history spans 16 years, with the latest figure at -$6.2 million for Q4 2025.

  • For Q4 2025, Net Income fell 89.38% year-over-year to -$6.2 million; the TTM value through Dec 2025 reached -$34.9 million, down 87.97%, while the annual FY2025 figure was -$63.4 million, 241.01% down from the prior year.
  • Net Income reached -$6.2 million in Q4 2025 per LCTX's latest filing, down from -$3.4 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$1.4 million in Q1 2021 to a low of -$28.0 million in Q4 2021.
  • Average Net Income over 5 years is -$7.2 million, with a median of -$6.1 million recorded in 2022.
  • The largest YoY upside for Net Income was 82.82% in 2021 against a maximum downside of 2946.44% in 2021.
  • A 5-year view of Net Income shows it stood at -$28.0 million in 2021, then skyrocketed by 77.43% to -$6.3 million in 2022, then grew by 25.42% to -$4.7 million in 2023, then soared by 31.06% to -$3.2 million in 2024, then crashed by 89.38% to -$6.2 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Net Income are -$6.2 million (Q4 2025), -$3.4 million (Q3 2025), and -$19.3 million (Q2 2025).